Devroe Eric 4

What Happened

• Eric Devroe, Chief Operating Officer of Acrivon Therapeutics (ACRV), had 613 shares withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units (RSUs). The filing reports the shares at $1.92 each for a total of $1,177. This is a withholding to cover taxes, not an open-market sale or a new purchase.

Key Details

• Transaction date: 2026-05-14; reported on Form 4 filed 2026-05-18 (timely).
• Amount: 613 shares withheld at $1.92 per share; total value reported $1,177.
• Transaction code: F (payment of exercise price or tax liability); footnote: shares withheld by issuer to satisfy mandatory tax withholding on RSU vesting.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: Filed May 18, 2026 — consistent with required Form 4 timing for a May 14 transaction.

Context

• Withholdings to cover taxes on vested RSUs are routine and do not indicate a personal decision to sell shares on the open market. They reduce the insider’s share count but generally are administrative rather than a signal about the insider’s view of the company.